MedPage Today

Upadacitinib Shows 1-Year Benefit in Pediatric IBD

Upadacitinib is not approved for pediatric IBD, though the selective JAK1 inhibitor is indicated for patients 2 years and older with juvenile idiopathic arthritis and psoriatic arthritis. The findings ...
Seeking Alpha

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023

– Late-breaking data from a head-to-head study evaluating SKYRIZI ® (risankizumab) versus STELARA ® (ustekinumab) in moderate to severe Crohn's disease will be presented – Analyses on clinical and ...
The Globe and Mail

AbbVie’s Korean Rinvoq Study in IBD Wraps Up, Setting the Stage for New Real‑World Data

AbbVie is running a post-marketing study in Korea titled “Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib (RINVOQ) in Korean Adult Patients With Ulcerative Colitis ...
Nasdaq

AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®

A total of 27 abstracts reinforce AbbVie leadership in advancing research and the standards of care across multiple gastroenterological conditions, including inflammatory bowel disease (IBD) and ...
Seeking Alpha

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

- Updated indication allows the use of RINVOQ ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable ...
Drug Store News

FDA approves new indication for AbbVie's Rinvoq

The updated indication allows the use of Rinvoq prior to the use of tumor necrosis factor blocking agents in certain patients. "At AbbVie, we are committed to addressing the ongoing needs of patients ...